Roslin Technologies develops and commercialises unique animal stem cell lines and related resources for the nascent cultivated meat industry. Its core product is high-quality animal cell lines intended to make cultivated meat safe, affordable and nutritious by enabling scale-up into competitive cell biomass. The company plans to expand its cell line portfolio and refine protocols for scale-up in partnership with customers, development collaborators and the University of Edinburgh. It also operates an insect venture focused on breeding improved insects for the emerging insect protein sector. Roslin was founded in 2017 as a venture between two investment firms and the University of Edinburgh and is based outside Edinburgh. The company is described as a revenue-generating commercial enterprise and has received sustained backing from Future Planet Capital, which first invested £10m in 2017. Roslin Technologies, connected to Edinburgh’s Roslin Institute (home of Dolly the sheep), develops stem cell line portfolios intended for use by food companies to produce cultivated meat. The company will use the funding to invest in development and commercialization of its cell lines and to build cultivated meat facilities. Leadership changes include the recruitment of Ernst van Orsouw as CEO, following his 15 years in agribusiness, and Jacqui Matthews serving as Chief Scientific Officer. Roslin says it is engaging with cultivated meat producers globally to drive adoption of its technology. The work is presented as part of a broader effort to improve the sustainability of meat production and respond to policy discussions such as those at COP26. No revenue or user metrics were disclosed in the article.

Total raised

$14M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2022